Safety findings from the final analysis of the phase 3 ARAMIS trial showed that the androgen receptor inhibitor remained well tolerated with longer treatment.
Jessica Skarzynski
Advertisement
Articles by Jessica Skarzynski
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer
5
